April 13, 2026 |
Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success.

Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success – including market analysis, sales teams, MSLs, training, launch meeting support, congress experiences, and product value demonstration.
Our client is a US biotechnology company that specializes in developing therapies for complex and chronic conditions. For many years, the firm has been working on what’s become the first new FDA-approved therapy of its kind in almost two decades.
Our client’s landmark product is an easy-to-use therapy that allows for rapid absorption and targets various receptors. In clinical trials, the treatment was shown to significantly reduce pain.
Primarily, the client needed a commercialization partner to rapidly set up a large, flexible nationwide sales team ready for the product launch in October 2025.
Read the full case study here.
This content was provided by Inizio
Latest Content from Inizio
In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy…
In emerging markets where primary care systems do not exist, the patient is the only constant in the journey
Pegasus, one of the most successful integrated healthcare communications consultancies in the UK, has today announced it has been acquired by UDG Healthcare plc, a FTSE 250 listed international provider…
Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?
Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.
Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients
Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch
Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out…
Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.
Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers…
